Principal Software Engineer - Image Processing
Elucid
Summary
Elucid is at the forefront of quantitative imaging, tissue characterization, and atherosclerotic plaque analysis, and we're continuing to grow our engineering organization! As a Principal Software Engineer - Image Processing, you will help design and build the software systems that power our AI-driven medical imaging platform. You'll collaborate closely with machine learning and visualization engineers to bring advanced imaging algorithms into production—designing and optimizing high-performance C++ pipelines and services that process large volumetric medical imaging datasets. Your work will focus on building reliable, scalable software that transforms complex imaging data into clinically meaningful insights, enabling physicians to better understand and treat cardiovascular disease with their patients.
Job description
The ideal candidate will have:
- 7+ years of experience developing image processing algorithms and software, ideally for medical or clinical products.
- Strong modern C++ skills, along with a solid foundation in software design principles and patterns, (eg. object-oriented design and template-based generic programming).
- Experience working with CT/CTA or other volumetric medical imaging data, including segmentation and registration techniques, as well as familiarity with standards such as DICOM.
- Experience optimizing software for performance, including algorithmic efficiency, memory usage, file I/O, and parallel execution, with tools and techniques such as multithreading, CUDA, and profiling.
- Experience building maintainable, high-performance production systems in collaborative, fast-paced engineering environments.
- Industry experience with machine learning is welcome but not required.
- Enthusiasm for working at the intersection of image processing, machine learning, and scalable software systems.
Work Location
- For local candidates in Greater Boston, we operate in a hybrid model with regular in-office collaboration. Candidates outside of the Boston area are invited to apply as fully-remote employees.
Requirements
- 7+ years of experience developing image processing algorithms and software, ideally for medical or clinical products.
- Strong modern C++ skills, along with a solid foundation in software design principles and patterns, (eg. object-oriented design and template-based generic programming).
- Experience working with CT/CTA or other volumetric medical imaging data, including segmentation and registration techniques, as well as familiarity with standards such as DICOM.
- Experience optimizing software for performance, including algorithmic efficiency, memory usage, file I/O, and parallel execution, with tools and techniques such as multithreading, CUDA, and profiling.
- Experience building maintainable, high-performance production systems in collaborative, fast-paced engineering environments.
- Industry experience with machine learning is welcome but not required.
- Enthusiasm for working at the intersection of image processing, machine learning, and scalable software systems.
Company overview
Elucid is a Boston-based medical technology company founded in 2013 that specializes in developing AI-powered imaging analysis software for cardiovascular disease assessment. The company's flagship product, PlaqueIQ, is the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue annotations by renowned pathologists. Elucid's technology brings precision patient care from oncology to cardiology by providing physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The company's software is designed to understand the root cause of cardiovascular disease deeply, offering objective and quantitative assessment of arterial plaque validated by histology. Elucid has raised over $150 million in funding and is pursuing an indication for FFRCT (fractional flow reserve derived from CT), uniquely derived from its PlaqueIQ technology, to measure coronary blockages non-invasively. The company's solutions are available for commercial use in the U.S., UK, EU, and South Korea, and recently gained broad CMS reimbursement for coronary plaque analysis using PlaqueIQ.